Opinion|Videos|November 19, 2024
Key Predictors of Survival in IPF: Findings From the IPF-PRO Registry
Author(s)Steven D. Nathan, MD
Key Takeaways
- The study aimed to identify predictors of long-term survival in idiopathic pulmonary fibrosis using the IPF-PRO Registry data.
- A retrospective cohort design was used, analyzing clinical, demographic, and physiological data to develop predictive models.
Steven Nathan, MD, discusses the abstract “Predicting Long-Term Survival in Patients With Idiopathic Pulmonary Fibrosis: Data From the IPF-PRO Registry,” which aimed to identify key predictors of long-term survival in IPF using data from the IPF-PRO Registry; the study employed a classification and regression tree model to analyze variables such as FVC percent predicted, oxygen use, BMI, and age, and found that factors such as oxygen use and FVC levels were strong predictors of survival beyond 5 years.
Advertisement
Episodes in this series
- Briefly describe the abstract “Predicting Long-Term Survival in Patients With Idiopathic Pulmonary Fibrosis: Data From The IPF-PRO Registry.”
- What was the objective of this study?
- How was this study designed/what methodology was used?
- What results were presented?
Advertisement
Related to this article
Ultimately, causality could not be established due to lack of data on disease severity and socioeconomic status, among others.
GRADE meta-analysis: hepatitis A vaccine blocks 96% in pre-exposure vaccination; outbreak response uses millions of doses, but post-exposure prophylaxis evidence is weak.
Alcohol abuse was the strongest post-trauma psychiatric predictor of cardiovascular events, with mood disorders more prominent among women.
Individuals with or at risk for arrhythmogenic cardiomyopathy had no added risk of ventricular arrhythmia from strength training, unlike endurance exercise.
A systematic review finds people with narcolepsy and idiopathic hypersomnia often stay employed but face work impairment and limited workplace support.
Laura Fabbri, MD, discusses bridging idiopathic pulmonary fibrosis (IPF) and oncology research and putting patients at the center of trial design.
Finerenone is the first new FDA-approved treatment in more than 30 years for adults with CKD associated with type 1 diabetes.
Karolinska Institutet reports ROR1 inhibitor KAN571C wipes out double‑resistant MCL after ibrutinib/venetoclax, spotlighting a promising target.
Advertisement
Advertisement